BS_NKRYMHEP
medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- medulloblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- medulloblastoma
- overall_survival_months
- 110.44678055190538
- age_years
- 7.093
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.595
- G2M_CHECKPOINT+0.548
- MYC_TARGETS_V1+0.385
- SPERMATOGENESIS+0.298
- PANCREAS_BETA_CELLS+0.280
- MITOTIC_SPINDLE+0.263
- DNA_REPAIR+0.216
- MYC_TARGETS_V2+0.126
- WNT_BETA_CATENIN_SIGNALING-0.012
- HEDGEHOG_SIGNALING-0.061
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.713
- INTERFERON_GAMMA_RESPONSE-0.616
- IL6_JAK_STAT3_SIGNALING-0.597
- TNFA_SIGNALING_VIA_NFKB-0.571
- ALLOGRAFT_REJECTION-0.568
- INFLAMMATORY_RESPONSE-0.566
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.489
- CHOLESTEROL_HOMEOSTASIS-0.470
- COAGULATION-0.457
- IL2_STAT5_SIGNALING-0.455
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_4PH1MBGR | medulloblastoma | — | 0.982 |
| 2 | BS_GNV89A5P | medulloblastoma | — | 0.972 |
| 3 | BS_HD4EJYE3 | medulloblastoma | — | 0.972 |
| 4 | BS_TE0GVDNG | medulloblastoma | — | 0.971 |
| 5 | BS_Y8D1F5WW | medulloblastoma | — | 0.970 |
| 6 | BS_HTEPAKCM | medulloblastoma | — | 0.970 |
| 7 | BS_QEYPFYHD | medulloblastoma | — | 0.969 |
| 8 | BS_4CP4T22V | medulloblastoma | — | 0.968 |
| 9 | BS_5PJCHF6V | medulloblastoma | — | 0.968 |
| 10 | BS_7XQRH69M | medulloblastoma | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 8 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.595 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.548 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.385 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.298 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.280 | Cobimetinib | — uncovered |
| MITOTIC_SPINDLE | 0.263 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.216 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.126 | Idelalisib | — uncovered |